Navigation Links
BioLineRx Reports Third Quarter 2013 Financial Results
Date:11/13/2013

JERUSALEM, Nov. 13, 2013 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, today reported its results for the third quarter ending September 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769)

Kinneret Savitsky, Ph.D., Chief Executive Officer of BioLineRx, stated, "As we approach the end of 2013, we see the Company's continued progress towards several significant catalysts over the next several quarters. For instance, one of our most advanced assets, BL-1040 for the prevention of ventricular remodeling post AMI, is progressing as scheduled at full steam in the PRESERVATION I CE-Mark registration trial. Fifty-five sites are currently open, including 14 in the U.S., and final results are expected in 2014."

Other highlights

BL-8040 (AML and other hematological indications):

  • Granted orphan drug designation by the FDA, allowing a faster clinical path toward commercialization 
  • Added Memorial Sloan Kettering Cancer Center in New York to join the Phase 2 multi-center study, bringing the total number of sites to eight
  • Received patent allowance through 2029 from the USPTO for method of obtaining stem cells
  • "During the third quarter, we made significant progress in our Phase 2 clinical trial for BL-8040, a best-in-class CXCR4 antagonist for the treatment of hematological cancers such as AML. In September, we received orphan drug status from the FDA, a designation with significant positive implications for BL-8040 as it advances through the clinic, including a seven-year market exclusivity period, clinical protocol assistance with the FDA, and federal grants and tax credits. We remain on track to deliver partial results from the trial by the end of this year, with final results expected in the second half of 2014. In addition, during the first half of 2014, we expect to commence additional clinical trials for BL-8040 in stem cell mobilization and chronic myeloid leukemia (CML)."

    BL-5010 (skin lesions):

  • Pivotal CE-Mark registration trial in Germany expected to commence by end of 2013, following receipt of regulatory approval
  • Finalized CRO and all other study vendor contracts in anticipation of study commencement
  • "We look forward to commencing the CE-Mark registration trial for BL-5010, our novel composition for the non-surgical removal of skin lesions, by the end of 2013, once we receive regulatory approval from the German regulatory authorities. We expect to announce results from the study around mid-2014. Positive results could potentially allow BL-5010 to enter the European market by the end of next year. During 2014, we also plan to expand BL-5010 into additional therapeutic indications, such as actinic keratosis, a pre-cancerous skin condition. In parallel with completing preparations for the pivotal study, we continue to engage in meaningful discussions with potential partners."

    BL-7010 (celiac disease):

  • Received approval to commence Phase 1/2 clinical trial from regulatory authorities in Finland
  • Finalized CRO and all other study vendor contracts in anticipation of study commencement by end of 2013
  • "Our unique therapeutic candidate for celiac disease, BL-7010, continues to generate a lot of excitement from notable scientists and physicians. Despite the unmet medical need and enormous size of the celiac market, there is no available treatment for the disease, and only a few clinical-stage products in development. We recently received approval from the Finnish regulatory authorities to commence a Phase 1/2 safety trial for BL-7010 at a world-leading site for celiac disease in Finland. We expect to begin this study by the end of 2013, and receive results by mid-2014. Assuming the study produces positive results, we hope to commence a Phase 2 efficacy study for BL-7010 by the end of next year." 

    New Board member:

  • Appointed BJ Bormann, Ph.D., to Board of Directors
  • "As we look forward to a year full of significant milestones for our Company, we are excited to welcome Dr. BJ Bormann to our Board of Directors. We expect her vast experience and knowledge in the healthcare space to assist us in reaching new heights in our discovery and partnering initiatives. Her most recent position as Senior Vice President and Worldwide Head of Therapeutic Alliances and Strategic Partnerships at Boehringer Ingelheim Pharmaceuticals, as well as her former role as Vice President, Strategic Alliances, at Pfizer, Inc., are testaments to her extensive credentials. We are confident that she will be an essential addition to our Board."

    Upcoming Analyst and Investor Day

  • Thursday, November 21, 2013 in New York City
  • "Later this month, Dr. Bormann, as well as our entire management team, will join several other distinguished speakers to discuss selected programs from our broad pipeline at our annual Analyst and Investor Day in New York. We are looking forward to this event, as it is a wonderful opportunity for our management team to engage directly with the investment community and provide detailed updates on our operational and developmental progress. As our programs advance through the clinic, we will continue to keep our loyal shareholders and potential investors fully updated of our progress," concluded Dr. Savitsky.

    Financial ResultsDuring the three-month and nine-month periods ended September 30, 2013 and 2012, no revenues were recorded.

    Research and development expenses for the three months ended September 30, 2013 were NIS 8.2 million ($2.3 million), a decrease of NIS 7.7 million ($2.2 million), or 48%, compared to NIS 15.9 million ($4.5 million) for the three months ended September 30, 2012. The decrease resulted primarily from lower expenses in 2013 associated with the CLARITY clinical trial in respect of BL-1020, due to termination of the trial in March 2013, partially offset by a ramp-up in spending on other clinical-stage projects introduced during 2012. Research and development expenses for the nine months ended September 30, 2013 were NIS 39.7 million ($11.3 million), a decrease of NIS 6.8 million ($1.9 million), or 15%, compared to NIS 46.5 million ($13.2 million) for the comparable period in 2012. Without regard to the NIS 6.0 million one-time reversal of amounts previously accrued to the OCS in respect of BL-1020, research and development expenses in the nine-month period decreased by NIS 0.8 million ($0.2 million). The reason for the decrease is similar to the one discussed above in the three-month comparison.

    Sales and marketing expenses for the three months ended September 30, 2013 were NIS 0.7 million ($0.2 million), compared to NIS 0.9 million ($0.3 million) for the three months ended September 30, 2012. The small decrease relates to lower professional fees and market research expenses as compared to the third quarter of last year. Sales and marketing expenses for the nine months ended September 30, 2013 were NIS 2.6 million ($0.7 million), substantially similar to the comparable period in 2012.

    General and administrative expenses for the three months ended September 30, 2013 were NIS 2.7 million ($0.8 million), an insignificant decrease compared to NIS 2.8 million ($0.8 million) for the three months ended September 30, 2012. General and administrative expenses for the nine months ended September 30, 2013 were NIS 9.8 million ($2.8 million), an increase of NIS 0.5 million ($0.2 million), or 5%, compared to NIS 9.3 million ($2.6 million) for the comparable period in 2012. The increase resulted primarily from a one-time expense for professional services incurred in the 2013 period.

    The Company's operating loss for the three months ended September 30, 2013 amounted to NIS 11.6 million ($3.3 million), compared with an operating loss of NIS 19.6 million ($5.5 million) for the comparable period in 2012. The Company's operating loss for the nine months ended September 30, 2013 amounted to NIS 52.1 million ($14.7 million), compared with an operating loss of NIS 58.5 million ($16.5 million) for the comparable period in 2012.

    The Company's net non-operating expenses amounted to NIS 4.6 million ($1.3 million) for the three months ended September 30, 2013, an increase of NIS 1.4 million ($0.4 million), compared to net non-operating expenses of NIS 3.2 million ($0.9 million) for the three months ended September 30, 2012. Non-operating expenses primarily relate to fair-value adjustments of liabilities on account of the warrants issued in the private and direct placements completed in February 2012 and 2013. Net non-operating income amounted to NIS 9.2 million ($2.6 million) for the nine months ended September 30, 2013, an increase of NIS 6.9 million ($1.9 million), compared to net non-operating income of NIS 2.4 million ($0.7 million) for the comparable 2012 period. Non-operating income for both periods primarily relate to fair-value adjustments of liabilities on account of warrants, as discussed above in the three-month comparison.

    Net financial expenses amounted to NIS 1.5 million ($0.4 million) for the three months ended September 30, 2013, a change of NIS 1.6 million ($0.5 million), compared to net financial income of NIS 0.2 million ($0.1 million) for the three months ended September 30, 2012. Net financial income and expenses result primarily from changes in the average exchange rate of the dollar in relation to the NIS during the respective periods, which have a direct effect on net assets denominated in dollars. Net financial expenses amounted to NIS 3.2 million ($0.9 million) for the nine months ended September 30, 2013, a change of NIS 7.5 million ($2.1 million), compared to net financial income of NIS 4.3 million ($1.2 million) for the comparable 2012 period. The reason for the change is similar to the one discussed above in the three-month comparison.

    The Company's net loss for the three months ended September 30, 2013 amounted to NIS 17.7 million ($5.0 million), compared with a net loss of NIS 22.6 million ($6.4 million) for the comparable period in 2012. The Company's net loss for the nine months ended September 30, 2013 amounted to NIS 46.1 million ($13.0 million), compared with a net loss of NIS 51.8 million ($14.7 million) for the comparable period in 2012.

    The Company held NIS 71.6 million ($20.3 million) in cash, cash equivalents and short-term bank deposits as of September 30, 2013.

    Net cash used in operating activities was NIS 55.9 million ($15.8 million) for the nine months ended September 30, 2013, compared with net cash used in operating activities of NIS 52.6 million ($14.9 million) for the nine months ended September 30, 2012. The NIS 3.3 million ($0.9 million) increase in net cash used in operating activities during the nine-month period in 2013, compared to the nine-month period in 2012, was primarily the result of a reduction in net trade payables and accruals during the 2013 period.

    Net cash used in investing activities for the nine months ended September 30, 2013 was NIS 17.5 million ($4.9 million), compared to net cash provided by investing activities of NIS 15.2 million ($4.3 million) for the nine months ended September 2012. The cash flows related to investing activities primarily stem from investments in, and maturities of, short-term bank deposits during the respective periods.

    Net cash provided by financing activities for the nine months ended September 30, 2013 was NIS 50.0 million ($14.1 million), compared to net cash provided by financing activities of NIS 52.2 million ($14.7 million) for the nine months ended September 2012. The cash flows from financing activities in the 2012 period reflect the private placement completed in February 2012. The cash flows from financing activities in the 2013 period reflect the direct placement to OrbiMed completed in February 2013, as well as funding under the share purchase agreement with Lincoln Park Capital.

    Conference Call and Webcast InformationBioLineRx will hold a conference call to discuss its third quarter 2013 results today, November 13, 2013, at 10:00 a.m. EST. The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx's website, www.biolinerx.com, and through www.kcsa.com. A presentation will be provided on BioLineRx's website to accompany management's remarks during the conference call. To dial into the conference call, please dial 1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call at www.biolinerx.com or www.kcsa.com. A dial-in replay of the call will also be available until November 16, 2013. To access the replay, please dial 1-888-254-7270 from the U.S. or +972-3-925-5927 internationally.

    (Tables follow)About BioLineRxBioLineRx is a publicly-traded biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs, as well as those with advantages over currently available therapies. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

    BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in late 2013; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study in late 2013.

    For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

    Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2013. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

    Contact:Garth Russell / Todd Fromer
    KCSA Strategic Communications
    1 212-896-1250 / 1 212-896-1215
    grussell@kcsa.com / tfromer@kcsa.com

    Tsipi Haitovsky
    Public Relations
    +972-3-6240871
    tsipih@netvision.net.il

     BioLineRx Ltd.CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION(UNAUDITED)Convenience
    translation into
    USDDecember 31,September 30,September 30,201220132013NIS in thousandsIn thousandsAssetsCURRENT ASSETSCash and cash equivalents

    68,339

    42,961

    12,146Short-term bank deposits

    11,459

    28,688

    8,111Prepaid expenses

    804

    809

    229Other receivables

    2,254

    875

    247Total current assets

    82,856

    73,333

    20,733,NON-CURRENT ASSETSRestricted deposits

    3,513

    1,933

    547Long-term prepaid expenses

    204

    144

    41Property and equipment, net

    3,172

    2,681

    758Intangible assets, net

    1,063

    911

    257Total non-current assets

    7,952

    5,669

    1,603Total assets90,808

    79,002

    22,336Liabilities and equityCURRENT LIABILITIESCurrent maturities of long-term bank loan

    137

    -

    -Accounts payable and accruals:Trade

    12,283

    12,564

    3,552OCS

    6,148

    -

    -Other

    5,443

    2,896

    819Total current liabilities

    24,011

    15,460

    4,371NON-CURRENT LIABILITIESRetirement benefit obligations

    143

    143

    41Warrants

    10,725

    13,165

    3,722Total non-current liabilities

    10,868

    13,308

    3,763COMMITMENTS AND CONTINGENT LIABILITIESTotal liabilities

    34,879

    28,768

    8,134EQUITYOrdinary shares

    1,837

    2,357

    666Share premium

    464,629

    504,309

    142,581Capital reserve

    33,802

    33,981

    9,607Accumulated deficit

    (444,339)

    (490,413)

    (138,652)Total equity

    55,929

    50,234

    14,202Total liabilities and equity90,808

    79,002

    22,336 BioLineRx Ltd.CONDENSED CONSOLIDATED INTERIM STATEMENT OF COMPREHENSIVE LOSS(UNAUDITED)Convenience translationinto USDThree monthsNine monthsThree months endedSeptember 30,Nine months endedSeptember 30,ended
    September 30,ended
    September 30,201220132012201320132013NIS in thousandsIn thousandsRESEARCH AND DEVELOPMENT EXPENSES, NET(15,848)

    (8,190)

    (46,523)

    (39,720)

    (2,316)

    (11,230)SALES AND MARKETING EXPENSES(912)

    (731)

    (2,626)

    (2,565)

    (207)

    (725)GENERAL AND ADMINISTRATIVE EXPENSES(2,834)

    (2,663)

    (9,315)

    (9,789)

    (752)

    (2,767)OPERATING LOSS(19,594)

    (11,584)

    (58,464)

    (52,074)

    (3,275)

    (14,722)NON-OPERATING INCOME (EXPENSES), NET(3,180)

    (4,627)

    2,351

    9,214

    (1,308)

    2,605FINANCIAL INCOME1,827

    501

    8,323

    2,484

    142

    702FINANCIAL EXPENSES(1,649)

    (1,956)

    (4,052)

    (5,698)

    (553)

    (1,611)COMPREHENSIVE LOSS FOR THE PERIOD(22,596)

    (17,666)

    (51,842)

    (46,074)

    (4,994)

    (13,026)NISUSDLOSS PER ORDINARY SHARE - BASIC AND DILUTED(0.13)

    (0.08)

    (0.31)

    (0.21)

    (0.02)

    (0.06) BioLineRx Ltd.CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS(UNAUDITED)Convenience translationinto USDNine months ended September 30,Nine months endedSeptember 30,201220132013NIS in thousandsIn thousandsCASH FLOWS - OPERATING ACTIVITIESComprehensive loss for the period

    (51,842)

    (46,074)

    (13,026)Adjustments required to reflect net cash used in
    operating activities (see appendix below)

    (724)

    (9,837)

    (2,782)Net cash used in operating activities

    (52,566)

    (55,911)

    (15,808)CASH FLOWS - INVESTING ACTIVITIESInvestments in short-term deposits

    (48,992)

    (104,127)

    (29,439)Maturities of short-term deposits

    64,801

    85,377

    24,138Maturities of restricted deposits

    -

    1,550

    438Purchase of property and equipment

    (545)

    (196)

    (55)Purchase of intangible assets

    (21)

    (96)

    (27)Net cash provided by (used in) investing activities

    15,243

    (17,492)

    (4,945)CASH FLOWS - FINANCING ACTIVITIESRepayments of bank loan

    (224)

    (127)

    (36)Issuance of share capital and warrants, net of issuance expenses

    52,453

    50,140

    14,176Proceeds from exercise of employee stock options

    *

    *

    *Net cash provided by financing activities

    52,229

    50,013

    14,140INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS14,906

    (23,390)

    (6,613)CASH AND CASH EQUIVALENTS – BEGINNINGOF PERIOD33,061

    68,339

    19,321EXCHANGE DIFFERENCES ON CASH AND CASH
    EQUIVALENTS4,931

    (1,988)

    (562)CASH AND CASH EQUIVALENTS - END OF PERIOD52,898

    42,961

    12,146* Less than 1,000 BioLineRx Ltd.APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS(UNAUDITED)Convenience translationinto USDNine months ended September 30,Nine months endedSeptember 30,201220132013NIS in thousandsIn thousandsAdjustments required to reflect net cash used in operating
    activities: Income and expenses not involving cash flows: Depreciation and amortization

    1,188

    870

    246Impairment of intangible assets

    -

    138

    39Long-term prepaid expenses

    (17)

    60

    17Exchange differences on cash and cash equivalents

    (4,931)

    1,988

    562Share-based compensation

    2,358

    2,400

    678Warrant issuance costs

    1,204

    470

    133Gain on adjustment of warrants to fair value

    (5,528)

    (10,191)

    (2,881)Interest and exchange differences on short-term deposits

    1,726

    1,521

    431Interest and linkage on bank loan

    (21)

    (10)

    (3)Interest and exchange differences on restricted deposits

    (31)

    30

    8(4,052)

    (2,724)

    (770)Changes in operating asset and liability items:Decrease in trade accounts receivable andother receivables

    2,193

    1,374

    388Increase (decrease) in accounts payable and accruals

    1,135

    (8,487)

    (2,400)3,328

    (7,113)

    (2,012)(724)

    (9,837)

    (2,782)Supplementary information on interest received in cash1,439

    449

    127 


    '/>"/>
    SOURCE BioLineRx Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
    2. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
    3. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
    4. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
    5. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
    6. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
    7. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
    8. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
    9. BioLineRx to Present at 15th International Celiac Disease Symposium
    10. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
    11. BioLineRx Appoints B. J. Bormann to Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. ... saving and improving the lives of pets, today announced ... of the New Animal Drug Application (NADA) for Zimeta™ ... field study (KB0120) of Zimeta for the control of ... Company. --> --> ...
    (Date:2/11/2016)... FRANCISCO , Feb. 11, 2016   Health ... advancement of new health technologies, announced today " 10 ... achievements in health tech over the past ten years.   ... For nearly a decade, Health 2.0 has served as ... showcased and connected with thousands of technologies, companies, innovators, ...
    (Date:2/11/2016)... Feb. 11, 2016  MiMedx Group, Inc. (NASDAQ: ... amniotic membrane and other birth tissues, human skin and ... and market advanced products and therapies, announced today that ... Global Healthcare Conference in New York ... Michael J. Senken , Chief Financial Officer and ...
    Breaking Medicine Technology:
    (Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center for ... General Hospital on April 5-7. The series is a multi-day, multi-workshop event designed ... workshops cover a broad range of topics, including coaching skills, the scientific method ...
    (Date:2/12/2016)... Las Vegas, NV (PRWEB) , ... February 12, 2016 , ... ... of North Las Vegas Mayor John J. Lee, Nevada Military Support Alliance president Scott ... newest Fisher House at the VA Southern Nevada Healthcare System. This will be ...
    (Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist Robert LaPrade, MD, ... in 2016 . The list consists of physicians establishing, leading and partnering with ambulatory ... , An Ambulatory Surgery Center, also known as an ASC, is a modern ...
    (Date:2/12/2016)... , ... February 12, 2016 , ... Donor Network West, ... California and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the ... hospital’s facilities as a way to accommodate a more certain time frame for donor ...
    (Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... southwest Houston and surrounding communities by continuing it’s commitment to act as Agents ... Promise. The organization works closely with area homeless families to fulfill immediate needs ...
    Breaking Medicine News(10 mins):